Table 1. Open in new tab Characteristics...

Characteristics

Overall population (n = 147)

FOLFIRI (n = 66)

5FU (n = 52)

p value

Demographic parameters

Center, n (%)

Besançon

60 (40.8)

20 (30.3)

20 (38.5)

Lille

55 (37.4)

36 (54.6)

11 (21.1)

Rennes

32 (21.8)

10 (15.1)

21 (40.4)

Age, median [IQR], years

60.0 [53.1–65.7]

66.2 [55.1–65.4]

56.4 [51.2–64.7]

.0411

Gender, n (%)

.9748

Male

80 (54.4)

37 (56.1)

29 (55.8)

Female

67 (45.6)

29 (43.9)

23 (44.2)

Familial history of cancer, n (%)

.9497

46 (42.2)

19 (43.2)

17 (42.5)

Yes

63 (57.8)

25 (56.8)

23 (57.5)

Missing

Personal history of cancer, n (%)

.0605

123 (86.0)

53 (82.8)

49 (94.2)

Yes

20 (14.0)

11 (17.2)

3 (5.8)

Missing

Pathologic parameters

Stage at diagnosis, n (%)

.2323

Localized

21 (14.3)

12 (18.2)

4 (7.7)

Locally advanced

35 (23.8)

12 (18.2)

9 (17.3)

Metastatic

91 (61.9)

42 (63.6)

39 (75.0)

Primary tumor site, n (%)

.0908

Head

79 (56.7)

29 (43.9)

31 (59.6)

Body and/or tail

68 (46.3)

37 (56.1)

21 (40.4)

Histological grade, n (%)

.7230

Well or moderately differentiated

52 (78.8)

27 (84.4)

17 (77.3)

Poorly differentiated or undifferentiated

14 (21.2)

5 (15.6)

5 (22.7)

Missing

Tumor extension

Stage at chemotherapy initiation, n (%)

.8508

Locally advanced

32 (21.8)

11 (16.7)

8 (15.4)

Metastatic

115 (78.2)

55 (83.3)

44 (84.6)

Number of metastatic sites, n (%)

.9811

32 (21.8)

11 (16.7)

8 (15.4)

87 (59.2)

41 (62.1)

33 (63.5)

≥2

28 (19.0)

14 (21.2)

11 (21.1)

Lymph node metastases, n (%)

.1604

133 (90.5)

57 (86.4)

49 (94.2)

Yes

14 (9.5)

9 (13.6)

3 (5.8)

Liver metastases, n (%)

.7166

57 (38.8)

22 (33.3)

19 (36.5)

Yes

90 (61.2)

44 (66.7)

33 (63.5)

Peritoneal metastases, n (%)

.5576

124 (84.4)

56 (84.9)

42 (80.8)

Yes

23 (15.6)

10 (15.1)

10 (19.2)

Lung metastases, n (%)

.9780

129 (88.8)

57 (86.4)

45 (86.5)

Yes

18 (12.2)

9 (13.6)

7 (13.5)

Other metastases, n (%)

.6294

143 (97.3)

63 (95.5)

51 (98.1)

Yes

4 (2.7)

3 (4.5)

1 (1.9)

Clinical parameters

Performance status (WHO), n (%)

.0258

56 (38.6)

22 (34.4)

25 (48.1)

85 (58.6)

41 (64.1)

25 (48.1)

≥2

4 (2.8)

1 (1.5)

2 (3.8)

Missing

Body mass index, kg/m²

23.1 [20.7–25.6]

23.0 [20.4–25.7]

23.2 [21.2–26.2]

.3500

Missing, n (%)

Pain, n (%)

.7355

90 (63.8)

45 (70.3)

33 (67.4)

Yes

51 (36.2)

19 (29.7)

16 (32.6)

Missing

Jaundice, n (%)

.9999

135 (94.4)

59 (92.2)

47 (94.0)

Yes

8 (5.6)

5 (7.8)

3 (6.0)

Missing

Ascites, n (%)

.6938

136 (95.8)

60 (93.8)

48 (96.0)

Yes

6 (4.2)

4 (6.2)

2 (4.0)

Missing

Biological parameters

Albumin, median [IQR], g/L

40.0 [35.0–43.0]

39.3 [35.5–42.1]

41.0 [38.5–44.0]

.1266

<35

18 (20.7)

9 (22.5)

2 (7.1)

.1083

≥35

69 (79.3)

31 (77.5)

26 (92.9)

Missing

Lymphocytes, median [IQR], mm³

1,530.0 [1,270.0–2,100.0]

1,510.0 [1,200.0–2,184.0]

1,540.0 [1,280.0–1,720.0]

.6683

<1,000

9 (9.5)

6 (12.8)

2 (6.1)

.4595

≥1,000

86 (90.5)

41 (87.2)

31 (93.9)

Missing

Neutrophil‐to‐lymphocyte ratio, median [IQR]

2.93 [2.13–4.46]

2.95 [2.14–5.85]

3.06 [2.13–4.30]

.7150

74 (77.9)

34 (72.3)

27 (81.8)

.3268

≥5

21 (22.1)

13 (27.7)

6 (18.2)

Missing

CA19‐9, median [IQR], UI/mL

605.0 [69.0–4,756.0]

310.0 [25.0–3,528.0]

562.5 [238.0–4,000.0]

.3818

<37

30 (23.1)

19 (32.2)

8 (17.4)

.0849

≥37

100 (76.9)

40 (67.8)

38 (82.6)

Missing

Previous treatment

Primary tumor resection, n (%)

.1883

Yes

22 (15.0)

12 (18.2)

5 (9.6)

125 (85.0)

54 (81.8)

47 (90.4)

Adjuvant chemotherapy, n (%)

.4294

Yes

17 (11.6)

8 (12.1)

48 (92.3)

130 (88.4)

58 (87.9)

4 (7.7)

Radiotherapy, n (%)

.9999

Yes

2 (1.4)

1 (1.5)

0 (0.0)

145 (98.6)

65 (98.5)

52 (100.0)

First‐line chemotherapy

Number of cycles of FOLFIRINOX, median [IQR]

9.0 [6.0–11.0]

.1056

<8 cycles

16 (24.2)

6 (11.5)

8–11 cycles

29 (44.0)

32 (61.6)

>12 cycles

21 (31.8)

14 (26.9)

Regimen after FOLFIRINOX, n (%)

FOLFIRI

66 (44.9)

FP monotherapy (capecitabine or LV5FU2)

52 (35.4)

FOLFOX

25 (17.0)

Other

4 (2.7)

RECIST best response, n (%)

.3339

Complete or partial response

69 (51.9)

31 (50.0)

31 (60.8)

Stability

61 (45.9)

29 (46.8)

20 (39.2)

Progression

3 (2.2)

2 (3.2)

0 (0.0)

Missing

Toxicity of grade 3 or 4, n (%)

.0302

88 (62.4)

37 (58.7)

39 (78.0)

Yes

53 (37.6)

26 (41.3)

11 (22.0)

Digestive

21 (39.6)

0 (0.0)

3 (27.3)

Hematology

8 (15.1)

1 (3.9)

5 (45.5)

Neurology

16 (30.2)

19 (73.1)

1 (9.1)

Other

8 (15.1)

6 (23.1)

2 (18.2)

Missing

Reason for discontinuation, n (%)

.8714

Progression

107 (73.3)

49 (75.4)

42 (80.8)

Toxicity

7 (4.8)

3 (4.6)

2 (3.8)

Other

32 (21.9)

13 (20.0)

8 (15.4)

Missing

Reintroduction of oxaliplatin and/or irinotecan, n (%)

<.001

61 (92.4)

25 (48.1)

Yes

5 (7.6)

27 (51.9)

FOLFIRINOX

4 (80.0)

19 (70.4)

FOLFIRI or FOLFIRI‐3

1 (20.0)

6 (22.2)

FOLFOX

0 (0.0)

2 (7.4)

Second‐line chemotherapy administration, n (%)

.3059

15 (22.7)

27 (51.9)

Yes

51 (77.3)

25 (48.1)

Gemcitabine

43 (84.3)

24 (96.0)

FOLFIRI

2 (3.9)

0 (0.0)

FOLFOX

3 (5.9)

0 (0.0)

Cisplatin

2 (3.9)

1 (4.0)

GEMOX

1 (2.0)

0 (0.0)

Characteristics

Overall population (n = 147)

FOLFIRI (n = 66)

5FU (n = 52)

p value

Demographic parameters

Center, n (%)

Besançon

60 (40.8)

20 (30.3)

20 (38.5)

Lille

55 (37.4)

36 (54.6)

11 (21.1)

Rennes

32 (21.8)

10 (15.1)

21 (40.4)

Age, median [IQR], years

60.0 [53.1–65.7]

66.2 [55.1–65.4]

56.4 [51.2–64.7]

.0411

Gender, n (%)

.9748

Male

80 (54.4)

37 (56.1)

29 (55.8)

Female

67 (45.6)

29 (43.9)

23 (44.2)

Familial history of cancer, n (%)

.9497

46 (42.2)

19 (43.2)

17 (42.5)

Yes

63 (57.8)

25 (56.8)

23 (57.5)

Missing

Personal history of cancer, n (%)

.0605

123 (86.0)

53 (82.8)

49 (94.2)

Yes

20 (14.0)

11 (17.2)

3 (5.8)

Missing

Pathologic parameters

Stage at diagnosis, n (%)

.2323

Localized

21 (14.3)

12 (18.2)

4 (7.7)

Locally advanced

35 (23.8)

12 (18.2)

9 (17.3)

Metastatic

91 (61.9)

42 (63.6)

39 (75.0)

Primary tumor site, n (%)

.0908

Head

79 (56.7)

29 (43.9)

31 (59.6)

Body and/or tail

68 (46.3)

37 (56.1)

21 (40.4)

Histological grade, n (%)

.7230

Well or moderately differentiated

52 (78.8)

27 (84.4)

17 (77.3)

Poorly differentiated or undifferentiated

14 (21.2)

5 (15.6)

5 (22.7)

Missing

Tumor extension

Stage at chemotherapy initiation, n (%)

.8508

Locally advanced

32 (21.8)

11 (16.7)

8 (15.4)

Metastatic

115 (78.2)

55 (83.3)

44 (84.6)

Number of metastatic sites, n (%)

.9811

32 (21.8)

11 (16.7)

8 (15.4)

87 (59.2)

41 (62.1)

33 (63.5)

≥2

28 (19.0)

14 (21.2)

11 (21.1)

Lymph node metastases, n (%)

.1604

133 (90.5)

57 (86.4)

49 (94.2)

Yes

14 (9.5)

9 (13.6)

3 (5.8)

Liver metastases, n (%)

.7166

57 (38.8)

22 (33.3)

19 (36.5)

Yes

90 (61.2)

44 (66.7)

33 (63.5)

Peritoneal metastases, n (%)

.5576

124 (84.4)

56 (84.9)

42 (80.8)

Yes

23 (15.6)

10 (15.1)

10 (19.2)

Lung metastases, n (%)

.9780

129 (88.8)

57 (86.4)

45 (86.5)

Yes

18 (12.2)

9 (13.6)

7 (13.5)

Other metastases, n (%)

.6294

143 (97.3)

63 (95.5)

51 (98.1)

Yes

4 (2.7)

3 (4.5)

1 (1.9)

Clinical parameters

Performance status (WHO), n (%)

.0258

56 (38.6)

22 (34.4)

25 (48.1)

85 (58.6)

41 (64.1)

25 (48.1)

≥2

4 (2.8)

1 (1.5)

2 (3.8)

Missing

Body mass index, kg/m²

23.1 [20.7–25.6]

23.0 [20.4–25.7]

23.2 [21.2–26.2]

.3500

Missing, n (%)

Pain, n (%)

.7355

90 (63.8)

45 (70.3)

33 (67.4)

Yes

51 (36.2)

19 (29.7)

16 (32.6)

Missing

Jaundice, n (%)

.9999

135 (94.4)

59 (92.2)

47 (94.0)

Yes

8 (5.6)

5 (7.8)

3 (6.0)

Missing

Ascites, n (%)

.6938

136 (95.8)

60 (93.8)

48 (96.0)

Yes

6 (4.2)

4 (6.2)

2 (4.0)

Missing

Biological parameters

Albumin, median [IQR], g/L

40.0 [35.0–43.0]

39.3 [35.5–42.1]

41.0 [38.5–44.0]

.1266

<35

18 (20.7)

9 (22.5)

2 (7.1)

.1083

≥35

69 (79.3)

31 (77.5)

26 (92.9)

Missing

Lymphocytes, median [IQR], mm³

1,530.0 [1,270.0–2,100.0]

1,510.0 [1,200.0–2,184.0]

1,540.0 [1,280.0–1,720.0]

.6683

<1,000

9 (9.5)

6 (12.8)

2 (6.1)

.4595

≥1,000

86 (90.5)

41 (87.2)

31 (93.9)

Missing

Neutrophil‐to‐lymphocyte ratio, median [IQR]

2.93 [2.13–4.46]

2.95 [2.14–5.85]

3.06 [2.13–4.30]

.7150

74 (77.9)

34 (72.3)

27 (81.8)

.3268

≥5

21 (22.1)

13 (27.7)

6 (18.2)

Missing

CA19‐9, median [IQR], UI/mL

605.0 [69.0–4,756.0]

310.0 [25.0–3,528.0]

562.5 [238.0–4,000.0]

.3818

<37

30 (23.1)

19 (32.2)

8 (17.4)

.0849

≥37

100 (76.9)

40 (67.8)

38 (82.6)

Missing

Previous treatment

Primary tumor resection, n (%)

.1883

Yes

22 (15.0)

12 (18.2)

5 (9.6)

125 (85.0)

54 (81.8)

47 (90.4)

Adjuvant chemotherapy, n (%)

.4294

Yes

17 (11.6)

8 (12.1)

48 (92.3)

130 (88.4)

58 (87.9)

4 (7.7)

Radiotherapy, n (%)

.9999

Yes

2 (1.4)

1 (1.5)

0 (0.0)

145 (98.6)

65 (98.5)

52 (100.0)

First‐line chemotherapy

Number of cycles of FOLFIRINOX, median [IQR]

9.0 [6.0–11.0]

.1056

<8 cycles

16 (24.2)

6 (11.5)

8–11 cycles

29 (44.0)

32 (61.6)

>12 cycles

21 (31.8)

14 (26.9)

Regimen after FOLFIRINOX, n (%)

FOLFIRI

66 (44.9)

FP monotherapy (capecitabine or LV5FU2)

52 (35.4)

FOLFOX

25 (17.0)

Other

4 (2.7)

RECIST best response, n (%)

.3339

Complete or partial response

69 (51.9)

31 (50.0)

31 (60.8)

Stability

61 (45.9)

29 (46.8)

20 (39.2)

Progression

3 (2.2)

2 (3.2)

0 (0.0)

Missing

Toxicity of grade 3 or 4, n (%)

.0302

88 (62.4)

37 (58.7)

39 (78.0)

Yes

53 (37.6)

26 (41.3)

11 (22.0)

Digestive

21 (39.6)

0 (0.0)

3 (27.3)

Hematology

8 (15.1)

1 (3.9)

5 (45.5)

Neurology

16 (30.2)

19 (73.1)

1 (9.1)

Other

8 (15.1)

6 (23.1)

2 (18.2)

Missing

Reason for discontinuation, n (%)

.8714

Progression

107 (73.3)

49 (75.4)

42 (80.8)

Toxicity

7 (4.8)

3 (4.6)

2 (3.8)

Other

32 (21.9)

13 (20.0)

8 (15.4)

Missing

Reintroduction of oxaliplatin and/or irinotecan, n (%)

<.001

61 (92.4)

25 (48.1)

Yes

5 (7.6)

27 (51.9)

FOLFIRINOX

4 (80.0)

19 (70.4)

FOLFIRI or FOLFIRI‐3

1 (20.0)

6 (22.2)

FOLFOX

0 (0.0)

2 (7.4)

Second‐line chemotherapy administration, n (%)

.3059

15 (22.7)

27 (51.9)

Yes

51 (77.3)

25 (48.1)

Gemcitabine

43 (84.3)

24 (96.0)

FOLFIRI

2 (3.9)

0 (0.0)

FOLFOX

3 (5.9)

0 (0.0)

Cisplatin

2 (3.9)

1 (4.0)

GEMOX

1 (2.0)

0 (0.0)

Table 1.

Open in new tab

Characteristics of the whole patient population (n = 147) and the population receiving FOLFIRI (n = 66) or 5FU maintenance (n = 52)

Characteristics	Overall population (n = 147)	FOLFIRI (n = 66)	5FU (n = 52)	p value
Demographic parameters
Center, n (%)
Besançon	60 (40.8)	20 (30.3)	20 (38.5)
Lille	55 (37.4)	36 (54.6)	11 (21.1)
Rennes	32 (21.8)	10 (15.1)	21 (40.4)
Age, median [IQR], years	60.0 [53.1–65.7]	66.2 [55.1–65.4]	56.4 [51.2–64.7]	.0411
Gender, n (%)				.9748
Male	80 (54.4)	37 (56.1)	29 (55.8)
Female	67 (45.6)	29 (43.9)	23 (44.2)
Familial history of cancer, n (%)				.9497
No	46 (42.2)	19 (43.2)	17 (42.5)
Yes	63 (57.8)	25 (56.8)	23 (57.5)
Missing	38	22	12
Personal history of cancer, n (%)				.0605
No	123 (86.0)	53 (82.8)	49 (94.2)
Yes	20 (14.0)	11 (17.2)	3 (5.8)
Missing	4	2	0
Pathologic parameters
Stage at diagnosis, n (%)				.2323
Localized	21 (14.3)	12 (18.2)	4 (7.7)
Locally advanced	35 (23.8)	12 (18.2)	9 (17.3)
Metastatic	91 (61.9)	42 (63.6)	39 (75.0)
Primary tumor site, n (%)				.0908
Head	79 (56.7)	29 (43.9)	31 (59.6)
Body and/or tail	68 (46.3)	37 (56.1)	21 (40.4)
Histological grade, n (%)				.7230
Well or moderately differentiated	52 (78.8)	27 (84.4)	17 (77.3)
Poorly differentiated or undifferentiated	14 (21.2)	5 (15.6)	5 (22.7)
Missing	81	34	30
Tumor extension
Stage at chemotherapy initiation, n (%)				.8508
Locally advanced	32 (21.8)	11 (16.7)	8 (15.4)
Metastatic	115 (78.2)	55 (83.3)	44 (84.6)
Number of metastatic sites, n (%)				.9811
0	32 (21.8)	11 (16.7)	8 (15.4)
1	87 (59.2)	41 (62.1)	33 (63.5)
≥2	28 (19.0)	14 (21.2)	11 (21.1)
Lymph node metastases, n (%)				.1604
No	133 (90.5)	57 (86.4)	49 (94.2)
Yes	14 (9.5)	9 (13.6)	3 (5.8)
Liver metastases, n (%)				.7166
No	57 (38.8)	22 (33.3)	19 (36.5)
Yes	90 (61.2)	44 (66.7)	33 (63.5)
Peritoneal metastases, n (%)				.5576
No	124 (84.4)	56 (84.9)	42 (80.8)
Yes	23 (15.6)	10 (15.1)	10 (19.2)
Lung metastases, n (%)				.9780
No	129 (88.8)	57 (86.4)	45 (86.5)
Yes	18 (12.2)	9 (13.6)	7 (13.5)
Other metastases, n (%)				.6294
No	143 (97.3)	63 (95.5)	51 (98.1)
Yes	4 (2.7)	3 (4.5)	1 (1.9)
Clinical parameters
Performance status (WHO), n (%)				.0258
0	56 (38.6)	22 (34.4)	25 (48.1)
1	85 (58.6)	41 (64.1)	25 (48.1)
≥2	4 (2.8)	1 (1.5)	2 (3.8)
Missing	2	2	0
Body mass index, kg/m²	23.1 [20.7–25.6]	23.0 [20.4–25.7]	23.2 [21.2–26.2]	.3500
Missing, n (%)	2	2	0
Pain, n (%)				.7355
No	90 (63.8)	45 (70.3)	33 (67.4)
Yes	51 (36.2)	19 (29.7)	16 (32.6)
Missing	6	2	3
Jaundice, n (%)				.9999
No	135 (94.4)	59 (92.2)	47 (94.0)
Yes	8 (5.6)	5 (7.8)	3 (6.0)
Missing	4	2	2
Ascites, n (%)				.6938
No	136 (95.8)	60 (93.8)	48 (96.0)
Yes	6 (4.2)	4 (6.2)	2 (4.0)
Missing	5	0	2
Biological parameters
Albumin, median [IQR], g/L	40.0 [35.0–43.0]	39.3 [35.5–42.1]	41.0 [38.5–44.0]	.1266
<35	18 (20.7)	9 (22.5)	2 (7.1)	.1083
≥35	69 (79.3)	31 (77.5)	26 (92.9)
Missing	60	26	24
Lymphocytes, median [IQR], mm³	1,530.0 [1,270.0–2,100.0]	1,510.0 [1,200.0–2,184.0]	1,540.0 [1,280.0–1,720.0]	.6683
<1,000	9 (9.5)	6 (12.8)	2 (6.1)	.4595
≥1,000	86 (90.5)	41 (87.2)	31 (93.9)
Missing	52	19	19
Neutrophil‐to‐lymphocyte ratio, median [IQR]	2.93 [2.13–4.46]	2.95 [2.14–5.85]	3.06 [2.13–4.30]	.7150
<5	74 (77.9)	34 (72.3)	27 (81.8)	.3268
≥5	21 (22.1)	13 (27.7)	6 (18.2)
Missing	52	19	19
CA19‐9, median [IQR], UI/mL	605.0 [69.0–4,756.0]	310.0 [25.0–3,528.0]	562.5 [238.0–4,000.0]	.3818
<37	30 (23.1)	19 (32.2)	8 (17.4)	.0849
≥37	100 (76.9)	40 (67.8)	38 (82.6)
Missing	17	7	6
Previous treatment
Primary tumor resection, n (%)				.1883
Yes	22 (15.0)	12 (18.2)	5 (9.6)
No	125 (85.0)	54 (81.8)	47 (90.4)
Adjuvant chemotherapy, n (%)				.4294
Yes	17 (11.6)	8 (12.1)	48 (92.3)
No	130 (88.4)	58 (87.9)	4 (7.7)
Radiotherapy, n (%)				.9999
Yes	2 (1.4)	1 (1.5)	0 (0.0)
No	145 (98.6)	65 (98.5)	52 (100.0)
First‐line chemotherapy
Number of cycles of FOLFIRINOX, median [IQR]	9.0 [6.0–11.0]			.1056
<8 cycles		16 (24.2)	6 (11.5)
8–11 cycles		29 (44.0)	32 (61.6)
>12 cycles		21 (31.8)	14 (26.9)
Regimen after FOLFIRINOX, n (%)
FOLFIRI	66 (44.9)
FP monotherapy (capecitabine or LV5FU2)	52 (35.4)
FOLFOX	25 (17.0)
Other	4 (2.7)
RECIST best response, n (%)				.3339
Complete or partial response	69 (51.9)	31 (50.0)	31 (60.8)
Stability	61 (45.9)	29 (46.8)	20 (39.2)
Progression	3 (2.2)	2 (3.2)	0 (0.0)
Missing	14	4	1
Toxicity of grade 3 or 4, n (%)				.0302
No	88 (62.4)	37 (58.7)	39 (78.0)
Yes	53 (37.6)	26 (41.3)	11 (22.0)
Digestive	21 (39.6)	0 (0.0)	3 (27.3)
Hematology	8 (15.1)	1 (3.9)	5 (45.5)
Neurology	16 (30.2)	19 (73.1)	1 (9.1)
Other	8 (15.1)	6 (23.1)	2 (18.2)
Missing	6	3	2
Reason for discontinuation, n (%)				.8714
Progression	107 (73.3)	49 (75.4)	42 (80.8)
Toxicity	7 (4.8)	3 (4.6)	2 (3.8)
Other	32 (21.9)	13 (20.0)	8 (15.4)
Missing	1	1	0
Reintroduction of oxaliplatin and/or irinotecan, n (%)				<.001
No		61 (92.4)	25 (48.1)
Yes		5 (7.6)	27 (51.9)
FOLFIRINOX		4 (80.0)	19 (70.4)
FOLFIRI or FOLFIRI‐3		1 (20.0)	6 (22.2)
FOLFOX		0 (0.0)	2 (7.4)
Second‐line chemotherapy administration, n (%)				.3059
No		15 (22.7)	27 (51.9)
Yes		51 (77.3)	25 (48.1)
Gemcitabine		43 (84.3)	24 (96.0)
FOLFIRI		2 (3.9)	0 (0.0)
FOLFOX		3 (5.9)	0 (0.0)
Cisplatin		2 (3.9)	1 (4.0)
GEMOX		1 (2.0)	0 (0.0)

Characteristics	Overall population (n = 147)	FOLFIRI (n = 66)	5FU (n = 52)	p value
Demographic parameters
Center, n (%)
Besançon	60 (40.8)	20 (30.3)	20 (38.5)
Lille	55 (37.4)	36 (54.6)	11 (21.1)
Rennes	32 (21.8)	10 (15.1)	21 (40.4)
Age, median [IQR], years	60.0 [53.1–65.7]	66.2 [55.1–65.4]	56.4 [51.2–64.7]	.0411
Gender, n (%)				.9748
Male	80 (54.4)	37 (56.1)	29 (55.8)
Female	67 (45.6)	29 (43.9)	23 (44.2)
Familial history of cancer, n (%)				.9497
No	46 (42.2)	19 (43.2)	17 (42.5)
Yes	63 (57.8)	25 (56.8)	23 (57.5)
Missing	38	22	12
Personal history of cancer, n (%)				.0605
No	123 (86.0)	53 (82.8)	49 (94.2)
Yes	20 (14.0)	11 (17.2)	3 (5.8)
Missing	4	2	0
Pathologic parameters
Stage at diagnosis, n (%)				.2323
Localized	21 (14.3)	12 (18.2)	4 (7.7)
Locally advanced	35 (23.8)	12 (18.2)	9 (17.3)
Metastatic	91 (61.9)	42 (63.6)	39 (75.0)
Primary tumor site, n (%)				.0908
Head	79 (56.7)	29 (43.9)	31 (59.6)
Body and/or tail	68 (46.3)	37 (56.1)	21 (40.4)
Histological grade, n (%)				.7230
Well or moderately differentiated	52 (78.8)	27 (84.4)	17 (77.3)
Poorly differentiated or undifferentiated	14 (21.2)	5 (15.6)	5 (22.7)
Missing	81	34	30
Tumor extension
Stage at chemotherapy initiation, n (%)				.8508
Locally advanced	32 (21.8)	11 (16.7)	8 (15.4)
Metastatic	115 (78.2)	55 (83.3)	44 (84.6)
Number of metastatic sites, n (%)				.9811
0	32 (21.8)	11 (16.7)	8 (15.4)
1	87 (59.2)	41 (62.1)	33 (63.5)
≥2	28 (19.0)	14 (21.2)	11 (21.1)
Lymph node metastases, n (%)				.1604
No	133 (90.5)	57 (86.4)	49 (94.2)
Yes	14 (9.5)	9 (13.6)	3 (5.8)
Liver metastases, n (%)				.7166
No	57 (38.8)	22 (33.3)	19 (36.5)
Yes	90 (61.2)	44 (66.7)	33 (63.5)
Peritoneal metastases, n (%)				.5576
No	124 (84.4)	56 (84.9)	42 (80.8)
Yes	23 (15.6)	10 (15.1)	10 (19.2)
Lung metastases, n (%)				.9780
No	129 (88.8)	57 (86.4)	45 (86.5)
Yes	18 (12.2)	9 (13.6)	7 (13.5)
Other metastases, n (%)				.6294
No	143 (97.3)	63 (95.5)	51 (98.1)
Yes	4 (2.7)	3 (4.5)	1 (1.9)
Clinical parameters
Performance status (WHO), n (%)				.0258
0	56 (38.6)	22 (34.4)	25 (48.1)
1	85 (58.6)	41 (64.1)	25 (48.1)
≥2	4 (2.8)	1 (1.5)	2 (3.8)
Missing	2	2	0
Body mass index, kg/m²	23.1 [20.7–25.6]	23.0 [20.4–25.7]	23.2 [21.2–26.2]	.3500
Missing, n (%)	2	2	0
Pain, n (%)				.7355
No	90 (63.8)	45 (70.3)	33 (67.4)
Yes	51 (36.2)	19 (29.7)	16 (32.6)
Missing	6	2	3
Jaundice, n (%)				.9999
No	135 (94.4)	59 (92.2)	47 (94.0)
Yes	8 (5.6)	5 (7.8)	3 (6.0)
Missing	4	2	2
Ascites, n (%)				.6938
No	136 (95.8)	60 (93.8)	48 (96.0)
Yes	6 (4.2)	4 (6.2)	2 (4.0)
Missing	5	0	2
Biological parameters
Albumin, median [IQR], g/L	40.0 [35.0–43.0]	39.3 [35.5–42.1]	41.0 [38.5–44.0]	.1266
<35	18 (20.7)	9 (22.5)	2 (7.1)	.1083
≥35	69 (79.3)	31 (77.5)	26 (92.9)
Missing	60	26	24
Lymphocytes, median [IQR], mm³	1,530.0 [1,270.0–2,100.0]	1,510.0 [1,200.0–2,184.0]	1,540.0 [1,280.0–1,720.0]	.6683
<1,000	9 (9.5)	6 (12.8)	2 (6.1)	.4595
≥1,000	86 (90.5)	41 (87.2)	31 (93.9)
Missing	52	19	19
Neutrophil‐to‐lymphocyte ratio, median [IQR]	2.93 [2.13–4.46]	2.95 [2.14–5.85]	3.06 [2.13–4.30]	.7150
<5	74 (77.9)	34 (72.3)	27 (81.8)	.3268
≥5	21 (22.1)	13 (27.7)	6 (18.2)
Missing	52	19	19
CA19‐9, median [IQR], UI/mL	605.0 [69.0–4,756.0]	310.0 [25.0–3,528.0]	562.5 [238.0–4,000.0]	.3818
<37	30 (23.1)	19 (32.2)	8 (17.4)	.0849
≥37	100 (76.9)	40 (67.8)	38 (82.6)
Missing	17	7	6
Previous treatment
Primary tumor resection, n (%)				.1883
Yes	22 (15.0)	12 (18.2)	5 (9.6)
No	125 (85.0)	54 (81.8)	47 (90.4)
Adjuvant chemotherapy, n (%)				.4294
Yes	17 (11.6)	8 (12.1)	48 (92.3)
No	130 (88.4)	58 (87.9)	4 (7.7)
Radiotherapy, n (%)				.9999
Yes	2 (1.4)	1 (1.5)	0 (0.0)
No	145 (98.6)	65 (98.5)	52 (100.0)
First‐line chemotherapy
Number of cycles of FOLFIRINOX, median [IQR]	9.0 [6.0–11.0]			.1056
<8 cycles		16 (24.2)	6 (11.5)
8–11 cycles		29 (44.0)	32 (61.6)
>12 cycles		21 (31.8)	14 (26.9)
Regimen after FOLFIRINOX, n (%)
FOLFIRI	66 (44.9)
FP monotherapy (capecitabine or LV5FU2)	52 (35.4)
FOLFOX	25 (17.0)
Other	4 (2.7)
RECIST best response, n (%)				.3339
Complete or partial response	69 (51.9)	31 (50.0)	31 (60.8)
Stability	61 (45.9)	29 (46.8)	20 (39.2)
Progression	3 (2.2)	2 (3.2)	0 (0.0)
Missing	14	4	1
Toxicity of grade 3 or 4, n (%)				.0302
No	88 (62.4)	37 (58.7)	39 (78.0)
Yes	53 (37.6)	26 (41.3)	11 (22.0)
Digestive	21 (39.6)	0 (0.0)	3 (27.3)
Hematology	8 (15.1)	1 (3.9)	5 (45.5)
Neurology	16 (30.2)	19 (73.1)	1 (9.1)
Other	8 (15.1)	6 (23.1)	2 (18.2)
Missing	6	3	2
Reason for discontinuation, n (%)				.8714
Progression	107 (73.3)	49 (75.4)	42 (80.8)
Toxicity	7 (4.8)	3 (4.6)	2 (3.8)
Other	32 (21.9)	13 (20.0)	8 (15.4)
Missing	1	1	0
Reintroduction of oxaliplatin and/or irinotecan, n (%)				<.001
No		61 (92.4)	25 (48.1)
Yes		5 (7.6)	27 (51.9)
FOLFIRINOX		4 (80.0)	19 (70.4)
FOLFIRI or FOLFIRI‐3		1 (20.0)	6 (22.2)
FOLFOX		0 (0.0)	2 (7.4)
Second‐line chemotherapy administration, n (%)				.3059
No		15 (22.7)	27 (51.9)
Yes		51 (77.3)	25 (48.1)
Gemcitabine		43 (84.3)	24 (96.0)
FOLFIRI		2 (3.9)	0 (0.0)
FOLFOX		3 (5.9)	0 (0.0)
Cisplatin		2 (3.9)	1 (4.0)
GEMOX		1 (2.0)	0 (0.0)

The population of the FOLFIRI group was older and performance status was higher than those of the 5FU group.

Abbreviations: 5FU, 5‐fluorouracil; CA19‐9, cancer antigen 19‐9; FP, fluoropyrimidine; GEMOX, gemcitabin oxaliplatin; IQR, interquartile range; LV5FU2, 5‐fluorouracil leucovorin; WHO, World Health Organization.

This Feature Is Available To Subscribers Only